Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update
Aerpio Pharmaceuticals (Nasdaq: ARPO) reported its Q2 2021 financial results, ending with $36.8 million in cash, down from $42.6 million at 2020's close. The firm is pursuing a merger with Aadi Bioscience, which requires shareholder approval and includes a $155 million PIPE financing. Q2 operating expenses decreased 16.9% year-over-year to $4.8 million, while R&D costs plummeted 79.7% to $0.7 million. However, general and administrative expenses rose 84.5% to $4.1 million, largely due to merger-related costs. The company reported a net loss of $4.4 million, compared to a profit of $9.3 million in Q2 2020.
- Entered a merger agreement with Aadi Bioscience, enhancing growth potential.
- Operating expenses decreased 16.9% year-over-year.
- Cash position remains strong at $36.8 million.
- Net loss of $4.4 million in Q2 2021, a significant decline from a profit in Q2 2020.
- General and administrative expenses increased 84.5%, indicating rising costs.
- Research and development expenses fell 79.7%, raising concerns about ongoing clinical programs.
- Ended second quarter 2021 with
$36.8 million in cash and cash equivalents - On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary closing conditions
CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update.
Key Business Update:
- On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., a Delaware company (“Aadi"), and Aspen Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Aerpio (“Merger Sub”), wherby Merger Sub will merge with and into Aadi with Aadi surviving as a wholly-owned subsidiary of Aerpio. The proposed merger was approved by the members of the board of directors of Aerpio (the “Board”) and the Board resolved to recommend approval of the proposed merger agreement to Aerpio’s shareholders. The closing of the proposed Aadi merger is subject to approval of the Aerpio shareholders and the satisfaction of certain closing conditions, including the completion of the Private Investment in Public Equity (“PIPE”) financing, described below, and other customary closing conditions.
- Subsequent to the closing of the proposed merger, Aerpio will change its name to “Aadi Bioscience, Inc.” and the combined public company will focus on advancing Aadi’s lead product candidate, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009)
- In connection with the execution of the merger agreement, Aerpio also entered into subscription agreements to raise an aggregate of
$155 million in a PIPE financing in shares of common stock and pre-funded warrants to purchase Aerpio common stock. The PIPE financing is expected to be consummated concurrently with the closing of the proposed merger, subject to customary closing conditions, and is contingent on the closing of the proposed merger. - If Aerpio is unable to satisfy the closing conditions in Aadi’s favor, or, if other applicable closing conditions are not satisfied, Aadi will not be obligated to complete the proposed merger. Under certain circumstances, Aerpio would be required to pay Aadi a termination fee of
$2.0 million if the proposed merger is terminated. - The terms of the merger agreement contemplate that a non-transferable contingent value right (“CVR”) will be distributed to Aerpio shareholders as of immediately prior to the effective time of the proposed merger, entitling CVR holders to receive net proceeds received by Aerpio, if any, associated with Aerpio’s legacy assets. The terms and conditions of the CVRs will be pursuant to a CVR Agreement that Aerpio will enter into prior to the closing of the proposed merger.
Second Quarter 2021 Financial Highlights
As of June 30, 2021, cash and cash equivalents totaled
For the three months ended June 30, 2021, operating expenses totaled
Research and development expenses for the three months ended June 30, 2021, decreased approximately
General and administrative expenses for the three months ended June 30, 2021, increased approximately
Restructuring expense for the six months ended June 30, 2021 was
Net loss attributable to common stockholders for the three months ended June 30, 2021, was
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. For more information, please visit www.aerpio.com.
Forward Looking Statements
This communication contains “forward-looking statements” based upon our current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements about the structure, timing and completion of the proposed transaction; the combined company’s listing on Nasdaq after the closing of the proposed transaction; the business of the combined company, including Aadi’s product candidates, the development therefor and the therapeutic potential thereof; the proposed PIPE and its terms; the opportunity for Aerpio shareholders to receive value from its legacy assets through the proposed contingent value rights, and the intended benefits from the Aspen’s collaboration with Gossamer Bio for GB004, including the continued development of GB004 and the milestone and royalty payments related to the collaboration. Actual results and the timing of events may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation: (i) risks associated with Aerpio’s ability to obtain the stockholder approval required to consummate the proposed transaction or to complete the PIPE financing, and the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction, including the PIPE financing, will not occur (ii) the response of Aerpio’s stockholders to the proposed transaction; (iii) risks related to Aerpio’s ability to manage its operating expenses and its expenses associated with the proposed transaction pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transaction; (v) the risk that as a result of adjustments to the exchange ratio, Aerpio stockholders and Aadi stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Aerpio’s common stock relative to the exchange ratio; (vii) unexpected costs, charges, expenditures or expenses resulting from the proposed transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (ix) Aerpio’s ability to retain personnel as a result of the announcement or completion of the proposed transaction; and (x) risks associated with the possible failure to realize certain anticipated benefits of the proposed transaction, including with respect to future financial and operating results and (xi) the risk that any potential payment of proceeds pursuant to the CVR Agreement may not be distributed at all or result in any value to Aerpio stockholders. Actual results and the timing of events may differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled “Risk Factors” in Aerpio’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 11, 2021 and in other filings that Aerpio makes and will make with the SEC, including those related to the proposed merger transaction with Aadi.
These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at www.sec.gov.
Contacts
Investors & Media:
Aerpio Pharmaceuticals, Inc.
Gina Marek
VP Finance
gmarek@aerpio.com
Or
Investors:
Irina Koffler
LifeSci Advisors
ikoffler@lifesciadvisors.com
Source: Aerpio Pharmaceuticals, Inc.
| AERPIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) | ||||||||
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 36,816 | $ | 42,605 | ||||
| Prepaid research and development contracts | - | 510 | ||||||
| Other current assets | 579 | 1,604 | ||||||
| Total current assets | 37,395 | 44,719 | ||||||
| Furniture and equipment, net | - | 122 | ||||||
| Operating lease right-of-use assets, net | 9 | 64 | ||||||
| Deposits | 20 | 20 | ||||||
| Total assets | $ | 37,424 | $ | 44,925 | ||||
| Liabilities and shareholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 2,198 | $ | 1,800 | ||||
| Current portion of operating lease liability | 10 | 67 | ||||||
| Total current liabilities | 2,208 | 1,867 | ||||||
| Total liabilities | 2,208 | 1,867 | ||||||
| Stockholders' equity: | ||||||||
| Capital | 190,617 | 189,609 | ||||||
| Accumulated deficit | (155,401 | ) | (146,551 | ) | ||||
| Total stockholders' equity | 35,216 | 43,058 | ||||||
| Total liabilities and stockholders' equity | $ | 37,424 | $ | 44,925 | ||||
| AERPIO PHARMACEUTICALS, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||
| Three months ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| License revenue | $ | - | $ | 15,000 | $ | - | $ | 15,000 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 719 | 3,549 | 2,948 | 5,378 | |||||||||||
| General and administrative | 4,052 | 2,195 | 6,188 | 4,481 | |||||||||||
| Restructuring expense | - | - | 1,238 | - | |||||||||||
| Total operating expenses | 4,771 | 5,744 | 10,374 | 9,859 | |||||||||||
| (Loss) income from operations | (4,771 | ) | 9,256 | (10,374 | ) | 5,141 | |||||||||
| Interest and other income | 363 | 20 | 1,525 | 216 | |||||||||||
| Net and comprehensive (loss) income | $ | (4,408 | ) | $ | 9,276 | $ | (8,849 | ) | $ | 5,357 | |||||
| Net (loss) income per common share basic and diluted | |||||||||||||||
| $ | (0.09 | ) | $ | 0.23 | $ | (0.19 | ) | $ | 0.13 | ||||||
| Weighted average common shares outstanding | |||||||||||||||
| Basic | 47,372,581 | 40,588,004 | 47,327,701 | 40,588,004 | |||||||||||
| Diluted | 47,372,581 | 40,905,288 | 47,327,701 | 40,747,960 | |||||||||||
FAQ
What are Aerpio Pharmaceuticals' Q2 2021 financial results?
What is the status of Aerpio's merger with Aadi Bioscience?
How did Aerpio's research and development expenses change in Q2 2021?
What impact did the merger have on Aerpio's administrative expenses?
How much capital is Aerpio raising through PIPE financing?
